Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 2 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma 1 Carcinoma, Ovarian Epithelial 1 B-cell Malignancies 1

Interventions

Dexamethasone 64 Lenalidomide 34 pomalidomide 33 Cyclophosphamide 33 Rituximab 31 Bortezomib 29 venetoclax 27 fludarabine 26 Gemcitabine 21 carfilzomib 20 Paclitaxel 19 pembrolizumab 17 daratumumab 16 Cisplatin 16 Carboplatin 15 Calcium Dobesilate 14 Azacitidine 14 ibrutinib 12 Docetaxel 12 Cytarabine 12 obinutuzumab 11 Nivolumab 11 durvalumab 10 Doxorubicin 10 Bevacizumab 10 selinexor 9 cemiplimab 9 blinatumomab 9 Injections 9 Cetuximab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × Clarithromycin × Clear all

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡